Could a common diabetes drug speed up heart and kidney healing?
NCT ID NCT06111768
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a diabetes drug called dapagliflozin can help people with heart failure who also develop kidney injury recover faster. About 30 adults will take the drug or usual care for three days. The main goal is to see if a larger trial is possible, not to prove the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin (a diabetes drug that lowers blood sugar and protects the kidneys)
What this could lead to
If it works, this could point toward a new way to help people with heart failure and kidney injury recover faster.
What could go wrong
This is a very small, early feasibility study with only 30 people. It is designed to see if a larger trial is possible, not to prove the drug works. The drug may not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIORENAL SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale New Haven Hospital
New Haven, Connecticut, 06520, United States